Alpha GPC
A choline donor with small, old cognition trials and a safety signal that caps the dose case.
C+
Evidence grade
C
Worth it
$15-25/month
Typical cost
DoseTrials and expert use cluster at 300 to 600 mg. Andrew Huberman’s published regimen is 300 to 600 mg, three to four times a week, before workouts or focused work (Ask Huberman Lab pages, checked October 2026). More is not better supported: the observational stroke signal in the safety notes was seen in long-term users, and the prudent read of this record is intermittent use inside the studied range, not daily escalation.
BasisAlpha GPC grades where citicoline grades, because the files rhyme: real but small human data, old cognition trials in impaired cohorts, acute performance signals that never converted into outcomes, and no large modern trial in healthy adults.
Alpha GPC (alpha-glycerophosphocholine) is a choline compound that reaches the brain and feeds acetylcholine production, the neurotransmitter behind the cholinergic nootropic claim. We grade Alpha GPC C+ on evidence and C for worth-it at about $15-25 per month.
What it does
Alpha GPC (alpha-glycerophosphocholine) is a choline compound that reaches the brain and feeds acetylcholine production, the neurotransmitter behind the cholinergic nootropic claim. It is sold for focus, memory, and power output. Its evidence shape matches citicoline, the other choline donor in this library, and it grades the same.
What the research says
May support memory and cognition in older adults
Evidence: emerging. The cognition case rests on small, short trials in older adults and dementia cohorts, mostly old and mostly low quality by current standards. No large modern randomized trial shows a benefit in healthy adults.
Acute signals for growth hormone and power output
Evidence: weak. Acute studies show transient growth-hormone release and small power-output signals. None has converted into a demonstrated training outcome: no trial shows alpha GPC making anyone stronger or better trained across a training block.
Alpha GPC grades where citicoline grades, because the files rhyme: real but small human data, old cognition trials in impaired cohorts, acute performance signals that never converted into outcomes, and no large modern trial in healthy adults. The stroke association and the TMAO pathway cap confidence at the doses social media runs. C+ is a plausible-mechanism grade with its ceiling stated.
What the experts say
Every position links to its source. We include skeptics alongside supporters.
Andrew Huberman
“Huberman says he typically takes 300 mg about three or four times weekly before workouts or cognitive work”
Source, 2026-10-24 Takes 300 mg of alpha GPC about three to four times a week, before workouts or focused work; 300 to 600 mg is the range he discusses. He mentions 600 mg of garlic as a way to help limit TMAO increases from chronic choline loads.
Is it worth it?
Evidence (C+) sits below the leaderboard floor, which caps the worth-it grade at C+; the derived value at about $20 a month lands at C. Derived from the October 2026 worth-it model.
Typical cost
$15-25/month
Common form, not a brand recommendation
Dosage context established
Trials and expert use cluster at 300 to 600 mg. Andrew Huberman’s published regimen is 300 to 600 mg, three to four times a week, before workouts or focused work (Ask Huberman Lab pages, checked October 2026). More is not better supported: the observational stroke signal in the safety notes was seen in long-term users, and the prudent read of this record is intermittent use inside the studied range, not daily escalation.
Worth-it leaderboard
Alpha GPC sits outside the worth-it top 20.
Alpha GPC sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Two cautions cap this record. Choline loads raise TMAO in feeding studies; Huberman states that he pairs alpha GPC with 600 mg of garlic for that concern. And a large observational cohort linked long-term alpha GPC use to higher stroke incidence. Association is not causation, and this record does not claim otherwise, but a signal in the exact long-term-use pattern that influencers promote belongs in the safety centre, not a footnote.
Longevity Lab Report
Alpha GPC news. Graded when it happens.
The grade on this page stays free. The email carries the news on alpha gpc: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-27
- 2026-10-26|Graded in the weekly deep dive of 2026-10-26 (C+), from the Oct 24 queue intake. Its evidence shape matches citicoline, the other choline donor in this library, and it grades the same. Grading also closes a gap on Andrew Huberman’s expert page, where alpha GPC was a documented item with no record behind it.
The week's longevity and biohacking news.
This grade for Alpha GPC rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.